Liangjiang strengthens healthcare industry

Liangjiang New Area will strengthen its high-end pharmaceutical manufacturing hub with the launch of an AI-enabled smart production base by Ansun (Chongqing) Life Science & Technology Co.

The base is expected to achieve an annual output value of over 1 billion yuan ($143 million). The first phase, focused on pharmaceutical formulation production, is slated to commence trial operations in the second half of 2026.

The facility features AI-enabled production workshops, an AI-driven warehousing and logistics center, and essential supporting systems such as power distribution. It will include a large-volume injectable production line and an oral solid dosage production line.

Chen Haitao, deputy general manager of Ansun, noted that the large-volume injectable production line will use an automated process for preparation, injection blow molding, filling, and sterilization, with an annual production capacity of up to 200 million bottles.

Meanwhile, the oral solid dosage production line will employ modern automated processes for weighing, mixing, granulation, blending, coating, and packaging, with an annual production capacity of 3 billion tablets, 3 billion capsules, and 2 billion sachets of granules.

Ansun, a Sino-US joint venture, brings over 20 years of expertise in new drug development, formulation process development, scale-up and optimization, process validation, registration, and commercialization. The company is particularly skilled in producing oral solid dosage forms, controlled-release formulations, injectables, and pulmonary inhalation systems.